Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program For Pain

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company developing non-invasive, topically administered medications, announced the initiation of its Phase 3 clinical program for Ketotransdel(TM), its novel topical cream based non-steroidal anti-inflammatory drug (”NSAID”) for pain. The Company has engaged Cato Research Ltd.

More: continued here

Filed under: Pain / Anesthetics on June 19th, 2008